We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GAIN:NASDAQGladstone Investment Corporation - Business Development Company Analysis

Data as of 2026-04-05 - not real-time

$14.38

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Gladstone Investment Corp (GAIN) trades at a trailing PE of 4.55, dramatically below the industry average of 16.57, and its price‑to‑book sits under 1 (0.96), indicating a potentially undervalued equity. The stock offers a robust 6.67% dividend yield with a modest payout ratio of 30%, suggesting the dividend is sustainable despite a debt‑to‑equity ratio near 96%. Technicals are neutral: the 20‑day SMA (14.07) is just above the 50‑day SMA (13.95), the MACD histogram is positive (0.018) and the signal is bullish, while price sits between a support of $13.11 and resistance of $14.54. Volume trends are decreasing and 30‑day volatility is about 23%, which combined with a beta of 0.76 points to moderate market sensitivity.
Given the cheap valuation, attractive yield, and solid ROE (~22%), the near‑term outlook leans toward holding, while the medium‑term case supports a buy on the expectation that the market will re‑price the stock closer to its DCF fair value of $6.38. Long‑term investors should monitor the high leverage and cash‑flow profile, but the BDC’s focus on lower‑middle‑market assets and a typical seven‑year investment horizon provide a stable foundation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Dividend yield remains attractive at 6.67%
  • Technicals are neutral with price near resistance
  • Decreasing volume adds short‑term uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation discount (PE 4.55 vs industry 16.57)
  • Sustainable dividend and low payout ratio
  • Positive MACD signal and modest beta indicating manageable volatility

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High debt‑to‑equity ratio (~96%) could constrain flexibility
  • Consistent ROE (~22%) and strong dividend support
  • BDCs' seven‑year investment horizon aligns with GAIN's strategy

Key Metrics & Analysis

Financial Health

Revenue Growth17.30%
Profit Margin118.55%
P/E Ratio4.6
ROE22.16%
ROA2.93%
Debt/Equity96.04
P/B Ratio1.0
Op. Cash Flow$-5745000
Free Cash Flow$29.8M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI57.2
Support$13.11
Resistance$14.54
MA 20$14.07
MA 50$13.95
MA 200$13.97
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

Fair Value$6.38
Target Price$14.83
Upside/Downside3.15%
GradeUndervalued
TypeValue
Dividend Yield6.67%

Risk Assessment

Beta0.76
Volatility23.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.